AVILEX PHARMA ApS: Financial statements 2023
CVR: 34896828
Source: annual report 2023, Danish Business Authority
01/01/2023 – 31/12/2023
AVILEX PHARMA ApS (CVR 34896828) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 0 and a net result of DKK -6,756,000 compared with DKK 28,600,000 the year before. Equity in the 2023 report amounted to DKK -1,839,000. The company had 2 employees in the financial year.
- Revenue
- DKK 0
- Gross Profit
- DKK 0
- Profit/Loss
- DKK -6,756,000
- Equity
- DKK -1,839,000
- Total Assets
- DKK 27,875,000
- Employees
- 2
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | 0 | 0 | -6.8 mio. | -1.8 mio. | 2 |
| 2022 | 45.5 mio. | 45.5 mio. | 28.6 mio. | 4.9 mio. | 2 |
| 2021 | - | - | -6.6 mio. | -25.3 mio. | 2 |
| 2020 | - | -3.1 mio. | -3 mio. | -18.6 mio. | 2 |
| 2019 | - | - | -3.7 mio. | -15.6 mio. | 4 |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationEvents in 2023
AVILEX PHARMA ApS has published its annual report for 2022. Revenue came to DKK 45,479,000, and the net result was DKK 28,600,000.
About AVILEX PHARMA ApS
AVILEX PHARMA ApS is a Danish company of the type Anpartsselskab based in København Ø, founded in 2012. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Kristian Strømgaard. The board consists of Raymond George Hill (chair), Camilla Petrycer Hansen, Jonathan Mark Treherne and Kristian Strømgaard. The company's owners include Novo Holdings A/S, MIKAEL SØNDERGÅRD THOMSEN ApS and KRISTIAN STRØMGAARD HOLDING ApS. The company has 4 employees (2025). In 2025, the company reported a net result of DKK -4,530,000 compared with DKK -4,428,000 the year before. Equity in the 2025 report amounted to DKK -10,797,000.